IMMU Stock Forecast: Win with a wise pick in the pharmaceutical industry
The article was written by Chloe Peng, Analyst at I Know First., Master of Science of Finance candidate at Brandeis University.
Summary:
- Though the clinical trials were influenced by the COVID-19 early this year, IMMU’s main product was approved in April by FDA, causing stock price to jump almost 30% instantly.
- There are many opportunities facing the company, for example, the market for breast cancer drug is expanding with a growth rate of around 10%.
- I believe the company’s revenue will triple in the next year and suggest you to buy the stock.